Overexpression of innate immune response genes in a model of recessive polycystic kidney disease  by Mrug, M. et al.
see commentary on page 7
Overexpression of innate immune response genes
in a model of recessive polycystic kidney disease
M Mrug1, J Zhou1, Y Woo2, X Cui1,3, AJ Szalai1,4, J Novak4, GA Churchill2 and LM Guay-Woodford1,5,6
1Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; 2The Jackson Laboratory, Bar Harbor,
Maine, USA; 3Department of Biostatistics, The University of Alabama at Birmingham, Birmingham, Alabama, USA; 4Department of
Microbiololgy, The University of Alabama at Birmingham, Birmingham, Alabama, USA; 5Department of Genetics, The University of
Alabama at Birmingham, Birmingham, Alabama, USA and 6Department of Pediatrics, The University of Alabama at Birmingham,
Birmingham, Alabama, USA
Defects in the primary cilium/basal body complex of renal
tubular cells cause polycystic kidney disease (PKD).
To uncover pathways associated with disease progression,
we determined the kidney transcriptome of 10-day-old
severely and mildly affected cpk mice, a model of recessive
PKD. In the severe phenotype, the most highly expressed
genes were those associated with the innate immune
response including many macrophage markers, particularly
those associated with a profibrotic alternative activation
pathway. Additionally, gene expression of macrophage
activators was dominated by the complement system factors
including the central complement component 3. Additional
studies confirmed increased complement component
3 protein levels in both cystic and non-cystic epithelia in the
kidneys of cpk compared to wild-type mice. We also found
elevated complement component 3 activation in two
other mouse-recessive models and human-recessive PKD.
Our results suggest that abnormal complement component
3 activation is a key element of progression in PKD.
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Polycystic kidney disease (PKD), a common genetic disorder
affecting over 600 000 people in the United States and 12.5
million worldwide, is a major cause of end-stage renal disease
in both children and adults.1 Autosomal-dominant PKD
(ADPKD; MIM 173900; 173910) occurs in 1:400–1:1000
individuals and is caused by mutations in one of two genes,
PKD1 or PKD2.2–5 Autosomal-recessive PKD (RPKD; MIM
263200) is less frequent (1:20 000 live births) and is caused by
defects in a single gene, PKHD1.6,7
The molecular basis of PKD is not well understood, but
critical clues have been provided by immunolocalization
studies, which demonstrated that multiple proteins encoded
by PKD-associated genes colocalize to the primary cilia on
the apical surface of renal epithelial cells. These include
proteins encoded by all three human PKD genes (PKD1,
PKD2, and PKHD1) as well as several protein products
disrupted in animal models of PKD, for example, orpk, cpk,
Inv, and Kif3a.8–10 Although the function of many PKD-
associated proteins is not known, they are likely important
for proper structure and/or function of the primary cilia.11–14
For example, proteins encoded by PKD1 and PKD2 may act
as mechanosensors or chemosensors on the cilia.15–17 Defects
in the primary cilium/basal body complex of renal epithelial
cells may trigger a myriad of secondary responses, for
example, changes in solute transport, cell proliferation,
apoptosis, extracellular matrix deposition, interstitial inflam-
mation, and fibrosis (summarized in Yoder et al.18). In
addition, mutated PKD genes might trigger abnormalities in
other (non-renal) cell types that may exacerbate PKD
progression through pathways not directly related to the
primary renal epithelial defect, for example, by increased
vascular dysfunction and vessel fragility as demonstrated in
mice homozygous for the mutant PKD1L allele.19
Earlier, pathways involved in PKD pathogenesis were
studied primarily in isolation. However, at least four recent
reports have sought to provide more comprehensive evalua-
tions of PKD-related transcriptional activity using high-
throughput gene expression profiling. Two of these studies
led to the identification of several tens of genes that were
differentially expressed, but the data analysis did not suggest
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2008 International Society of Nephrology
Received 10 April 2007; revised 10 August 2007; accepted 21 August
2007
Correspondence: M Mrug, Division of Genetic and Translational Medicine,
Department of Medicine, University of Alabama at Birmingham, 752 Kaul
Human Genetics Building, 720 20th Street South, Birmingham, Alabama
35294, USA. E-mail: mmrug@uab.edu or
LM Guay-Woodford, Division of Genetic and Translational Medicine,
Department of Medicine, University of Alabama at Birmingham, 740 Kaul
Human Genetics Building, 720 20th Street South, Birmingham, AL 35294,
USA. E-mail: lgw@uab.edu
Kidney International (2008) 73, 63–76 63
the activation of any integrated molecular pathway.20,21
A more recent study of end-stage ADPKD kidneys suggested
that epithelial to fibroblast transition is the most prominent
PKD-specific transcriptional abnormality.22 On the other
hand, transcriptome profiling of kidneys form the Cy rat
model of PKD indicated a prominent role for abnormalities
in extracellular matrix metabolism, in particular those related
to fibrosis and adhesion to the extracellular matrix.23 Taken
together, these studies failed to identify a common set of
genetic pathways involved in PKD progression. These
differences may reflect different experimental designs and/
or difference in the PKD model studied. Additional factors
that could reduce the sensitivity of these gene expression
profiles included a small number of studied tissues/
individuals (for example, n¼ 2)20 as well as uncontrolled
variability in a large number of genetic, environmental, age,
tissue sampling, and processing factors that may influence
gene expression.
Compared to the human population, animal models are
expected to provide more consistent gene expression
profiling data because they permit use of experimental
designs that reduce the effects of confounding genetic,
environmental, and technical variables. Among RPKD
models, the cpk mouse is one of the most extensively
characterized.24,25 The cpk mutation (Cys1cpk), which arose
spontaneously in the C57BL/6J-Pldnpa (B6) strain, involves a
tandem deletion that leads to the truncation of a novel, cilia-
associated protein called cystin.8,13 The renal phenotype of
the cpk mouse is characterized by massive cystic involvement
of the collecting ducts, a pattern that strongly resembles
human RPKD.26 In the liver, ductal plate malformation gives
rise to a biliary dysgenesis phenotype that closely resembles
congenital hepatic fibrosis observed in human RPKD.
Other commonly used RPKD models include bpk and
orpk mice. The bpk mutation (Bicc1bpk), involving the
insertion of 2-bp into exon 22 of the gene encoding bicaudal
C (Bicc1), arose spontaneously in the BALB/c strain,27 and
its renal and biliary phenotypes closely resemble the cpk
and human RPKD abnormalities.28 The orpk mouse has a
more complex phenotype with renal cysts appearing initially
in proximal tubular segment and later (at 2–3 weeks of age)
in collecting ducts.29 The orpk mutation (Ift88Tg737Rpw),
generated by insertional mutagenesis in FVB/N oocytes,
disrupts expression of polaris, a primary cilia associated
protein.30
We have recently described several quantitative trait
loci that modulate RPKD-related phenotypes in a (B6-cpk/
þ CAST)F1 intercross.31 One of the strategies to prioritize
positional quantitative trait loci gene candidates was gene
expression profiling of mildly and severely affected kidneys
from this cross. In this study, we present a comprehensive
evaluation of whole-genome expression profiling of these
cpk kidneys, and based on the data, we have generated
hypotheses about the biological processes that distinguish
disease progression in mildly vs severely affected RPKD
kidneys.
RESULTS
Identification of genes differentially expressed in mildly vs
severely affected kidneys from cpk mice
We examined the gene expression profiles of seven most
mildly and seven most severely affected cystic kidneys
selected from the F2 cohort of affected cpk mice (n¼ 461).
These mice were generated in (B6-cpk/þ CAST)F1 inter-
crosses. The severity of their phenotypes were defined by
kidney length, weight, and volume.31 Transcriptional profiles
of these extreme kidney phenotypes were obtained with 14
Affymetrix 430 2.0 arrays. Among B40 000 transcripts
represented on each array, the differential expression of
B2700 was statistically significant (Po0.005) after adjusting
for multiple testing. The expression of B100 genes differed
42-fold (the most prominently overexpressed genes).
Expression of about half of these 100 transcripts was
increased in severely affected cpk kidneys, whereas the
remaining transcripts had decreased expression.
Array data validity is suggested by technical parameters and
biological relevance
Large-scale validation of the Affymetrix 430 2.0 data was
obtained by repeating the analyses with Affymetrix U74Av2
arrays. Strong correlation between the 430 2.0 and U74Av2
data sets (r¼ 0.72 for all transcripts, r¼ 0.90 for differentially
expressed genes with Po0.05 after adjusting for multiple
testing) provided technical validation of the 430 2.0 data
(Figure 1).
Biological relevance of the array data also suggests its
validity. For example, severely affected kidneys consistently
underexpressed genes that are known to be expressed at
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Figure 1 | Correlation between gene profiling results from two
different GeneChip platforms. Validation of the 14 Affymetrix 430
2.0-derived gene expression profiles was performed by repeating the
gene expression analyses using 14 low-density Affymetrix U74Av2
arrays. Strong correlation of gene expression across these two array
platforms (r¼ 0.72 for all genes (black crosses); r¼ 0.90 for the
differentially expressed genes with the false discovery rate (FDR)
adjusted Po0.05 (a¼ 0.05; blue circles)) provided a formal large-scale
validation of the gene expression data obtained.
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higher levels in normal kidneys vs other normal tissues.32
These genes are associated with major metabolic pathways, in
particular with the generation of precursor metabolites and
energy (for example, ATP biosynthesis, fatty acid oxidation,
oxidative phosphorylation, carboxylic acid metabolism,
amino-acid metabolism, sulfur metabolism, aromatic com-
pound metabolism, and steroid metabolism). The observed
gene downregulation is consistent with the reduction of
functional renal parenchyma in advanced PKD (summarized
in Madsen and Tisher33). On the other hand, expression of
several genes that were previously found to be overexpressed
in PKD kidneys, for example, Aqp2, Avpr2, Clu, Col1, Egfr,
Fn1, Fos, Hmox1, Jun, and Myc, was increased in severely vs
mildly affected cpk kidneys. In addition, we found over-
expression of markers associated with RPKD-related vs
RPKD-unrelated renal epithelial cell types, using a list of
nephron segment-specific markers (summarized in Madsen
and Tisher33) validated by serial analysis of gene expression.34
Consistent with previous studies of cpk mice that described
replacement of renal parenchyma by cysts derived from
principal cells of collecting ducts,35 our array analyses
demonstrated that the expression of the principal cell
markers examined was increased in severely affected cpk
kidneys. In comparison, the expression of markers associated
with other nephron segments was decreased (13 markers) or
unchanged (seven markers) (see Table 1).
Table 1 | Expression of principal cell markers is increased in severely affected cpk kidneys
Segment Subsegment Cells Marker Gene Expression Fold change
Glomerulus Endothelial
cells
VEGF-R Flt1(VEGFR1) — —
Visceral
epithelial cells
VEGF Vegfa Decreased 1.3
CD2AP Cd2ap — —
Heymann antigen (megalin) Lrpap1 Decressed 1.5
Heymann antigen (Lrp2) Lrp2 — —
collagen type 4 Col4 — —
Mesangial
cells
angiotensin-R, type 1 Agtr1 Decreased 1.4
Macula densa BSC-1,Na+,K+,2Cl-cotransporter
bumetanide sensitive
Slc12a1 Decreased 1.6
Proximal tubule Pars convoluta Heymann antigen (Lrp2) Lrp2 — —
maltase Mgam — —
cubilin Cubn Decreased 1.9
L-alpha-OH-acid oxidase Hao2 — —
D-AA oxidase Dao1 Decreased 1.4
Distal tubule Thick ascending
limb
ROMK Kcnj1 Decreased 1.4
BSC-1,Na+,K+,2Cl-cotransporter
bumetanide sensitive
Slc12a1 Decreased 1.6
Ca++ sensing receptor Casr Decreased 1.2
parathyroid hormone receptor Pthr1 Decreased 2.2
Distal convoluted TSC, Na/Cl cotransporter thiazide
sensitive
Slc12a3 Decreased 2.0
11-beta-OH-steroid dehydrogenase
2
Hsd11b2 — —
Calbindin Calb1 — —
FXYD domain containing ion
transport regulator 2
Fxyd2 Decreased 1.3
transient receptor potential
cation channel
Trpm6 — —
Connecting
segment
kallikrein (renal/pancreas/
salivary -KLK1)
Klk6 Decreased 2.6
calbindin Calb1 — —
TSC, Na/Cl cotransporter thiazide
sensitive
Slc12a3 Decreased 2.0
Collecting duct Cortical Intercalated
cells (35–40%)
vacuolar H+ ATPase Atp6v1b1 Decreased 1.5
AE-4, anion exchanger Slc4a9 — —
Principal cells
(60–75%)
ENAC, sodium channel amiloride
sensitive
Scnn1b Increased 1.6
vasopressin receptor Avpr2 Increased 1.3
aquaporin 2 Aqp2 Increased 1.9
Outer medullary Principal cells
(60–75%)
ENAC, sodium channel amiloride
sensitive, alpha unit
Scnn1a Increased 1.6
ENAC, sodium channel amiloride
sensitive, beta unit
Scnn1b Increased 1.6
aquaporin 2 Aqp2 Increased 1.9
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Pathway analyses identified innate immune response as the
most prominent transcriptional feature in severely affected
cpk kidneys
We performed functional annotation of differentially ex-
pressed genes in severely vs mildly affected cpk kidneys using
the Expression Analysis Systematic Explorer and additional
tools from the Database for Annotation, Visualization and
Integrated Discovery (version 2.1). Using these tools, we
performed functional annotation analyses that allowed
identification of enriched biological themes within a gene
data set, particularly Gene Ontology (GO) terms for
biological processes. These analyses revealed that severely
affected kidneys underexpressed those metabolic genes that
represent a hallmark of the normal kidney transcriptome,32
as described above. In contrast, severely affected cpk kidneys
overexpressed genes associated with biological processes
related to development, cell adhesion, chemotaxis, response
to external stimulus (that is, wounding), and immune
response (Table 2). Similar results were obtained when
associations with GO terms and relationship of the GO terms
within the data set were visualized using the VisuaL
Annotation Display (Figure 2a). However, these functional
annotations are based on presence (or absence) of specific
genes in the analyzed data set and are not influenced by fold
Table 2 | Biological processes up-regulated in severely affected cpk kidneys
Gene ontology Term Count % P-value
All genes with significantly increased expression; Po0.005 (1195 DAVID IDs)
GO:0007275 Development 193 16.15 4.94E19
GO:0048513 Organ development 114 9.54 4.40E18
GO:0007155 Cell adhesion 76 6.36 2.80E14
GO:0009653 Morphogenesis 101 8.45 3.38E13
GO:0030154 Cell differentiation 96 8.03 6.02E12
GO:0007610 Behavior 40 3.35 6.44E10
GO:0009887 Organ morphogenesis 60 5.02 8.34E10
GO:0042330 Taxis 24 2.01 1.59E09
GO:0006935 Chemotaxis 24 2.01 1.59E09
GO:0007626 Locomotory behavior 30 2.51 3.36E09
GO:0007010 Cytoskeleton organization and
biogenesis
55 4.60 3.57E09
GO:0048518 Positive regulation of biological
process
72 6.03 9.83E09
GO:0009605 Response to external stimulus 61 5.10 3.38E08
GO:0007242 Intracellular signaling cascade 88 7.36 3.50E08
GO:0008283 Cell proliferation 46 3.85 9.30E08
GO:0000904 Cellular morphogenesis 47 3.93 1.04E07
GO:0006954 Inflammatory response 27 2.26 1.45E07
GO:0006955 Immune response 82 6.86 2.06E07
GO:0048522 Positive regulation of cellular process 60 5.02 2.60E07
GO:0001944 Vasculature development 26 2.18 6.89E07
Genes with 42-fold increase in expression (63 DAVID IDs)
GO:0006955 Immune response 15 23.81 1.77E08
GO:0009613 Response to pest, pathogen, or
parasite
13 20.63 4.16E08
GO:0051707 Response to other organism 13 20.63 6.04E08
GO:0006952 Defense response 15 23.81 3.07E07
GO:0009607 Response to biotic stimulus 15 23.81 4.36E07
GO:0006817 Phosphate transport 6 9.52 1.02E06
GO:0006950 Response to stress 14 22.22 2.09E6
GO:0006959 Humoral immune response 7 11.11 5.00E06
GO:0016064 Humoral defense mechanism (sensu
Vertebrata)
5 7.94 1.91E05
GO:0015698 Inorganic anion transport 6 9.52 3.75E05
GO:0006958 Complement activation, classical
pathway
4 6.35 4.00E05
GO:0006953 Acute-phase response 4 6.35 3.99E5
GO:0050874 Organismal physiological process 19 30.16 8.34E05
GO:0006820 Anion transport 6 9.52 8.34E05
GO:0006956 Complement activation 4 6.35 0.0002
GO:0045087 Innate immune response 4 6.35 0.0003
GO:0006954 Inflammatory response 5 7.94 0.0007
GO:0009605 Response to external stimulus 7 11.11 0.0027
GO:0009611 Response to wounding 6 9.52 0.0050
GO:0006960 Antibacterial humoral response (sensu
Protostomia)
2 3.17 0.0052
DAVID, Database for Annotation, Visualization and Integrated Discovery.
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changes in differential gene expression. To identify biological
processes related to most highly overexpressed genes, we
repeated all analyses with a subset of genes whose expression
was changed more than twofold between severely and mildly
affected cpk kidney transcriptomes. These analyses revealed
that the most prominently (greater than twofold) over-
expressed genes were associated with immune response, in
particular with the acute-phase response and complement
activation (Table 2 and Figure 2b) that form the core of the
humoral component of innate immunity.
To further investigate biological processes associated with
severe cpk renal phenotype, we used a complementary
in silico approach and queried the suite of databases maintained
at NCBI (for example, PubMed and Gene) for biological
functions of individual overexpressed genes. These analyses
identified immune response as the most common association
for genes overexpressed in severely affected cpk kidneys and
confirmed the results generated with the Database for
Annotation, Visualization and Integrated Discovery and
VisuaL Annotation Display tools. These in silico analyses
also revealed that innate immune system markers dominated
among genes with the highest (2.5- to 4.7-fold) over-
expression (Table 3). Among the most highly overexpressed
transcripts, 1.5- to 4.7-fold (on average 2.7-fold), was a
subset of genes encoding acute-phase reactants; in addition to
10 genes shown in Table 3, acute-phase reactant encoding
genes included a1-antichymotrypsin (Serpina3n), a2-anti-
plasmin (Serpinf1), hemoxygenase 1 (Hmox1), C1-inhibitor
(Serping1), and lipopolysaccharide-binding protein (Lpb). In
addition, the in silico analysis revealed that many of the
overexpressed genes are markers of macrophages (Table 4),
the cellular component of innate immunity. Some of these
markers, including Arg1, Ccl17, Ccr5, F13a, Fcer1g, Mrc1,
Il4ra, Il10ra, Il13ra1, and Saa3, are associated with alter-
natively activated (M2) macrophage phenotype (reviewed in
Gordon36) that facilitates wound healing and fibrosis.
Immunocompetence of these putative macrophages is
indicated by the overexpression of genes encoding CD64
and CD32 (Fcgr1 and Fcgr2b), CD14, TLR-4, complement
receptor 3 (CR3; CD11b/CD18), and CD123, an interleukin
(IL)-3 growth factor receptor. Their functional activation is
suggested by the overexpression of Abca1 and Slpi, and the
phagocytic activity by the overexpression of Acta2, Actc1,
Actg2, Pxn. The expression of a gene encoding the receptor
for major macrophage activator interferon-g (Ifngr2) was
increased, but there was no change in the expression of
interferon-g ligand (Ifng). Finally, the overexpression of
multiple monocyte/macrophage chemoattractants, for exam-
ple, monocyte chemoattractant protein-2, -3, and -5 (MCP-2,
MCP-3, and MCP-5; Ccl8, Ccl7, and Ccl12) is consistent with
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Figure 2 | Output of VisuaL Annotation Display analysis of genes overexpressed in severely affected cpk kidneys informed by GO
Biological Process annotations. (a) Analysis of all genes overexpressed in severely affected cpk kidneys grouped these genes into five
major nodes related to development, response to wounding, chemotaxis, cell adhesion, and immune system process . (b) Analysis with a
subset of the most prominently (greater than twofold) overexpressed genes identified acute-phase response, complement activation, and
related immunological GO terms as the most prominent biological processes in severely affected cpk kidneys. Depending on the thresholds
used for pruning or collapsing of the tree, the graphical display contains a collection of collapsed nodes, drawn as small circles, and
expanded nodes, containing text. The arrows represent relationships of individual nodes within the ontology. Numbers at the bottom of
each expanded node represent the P-value, number of genes in the query set annotated to that node, and the number genes in GO database
annotated to that node.
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an accelerated active recruitment of the monocyte/macro-
phage-like cells to the severely affected cpk kidneys.
The overexpression of genes encoding macrophage-asso-
ciated markers appeared to be specific to RPKD progression
rather than reflect a nonspecific immmunological response.
There was no change in the expression of genes encoding
markers of other immune cells, for example, dendritic cells
(CD8a, Dec205, CD11c, CD40, CD80, chemokine receptor 1),
lymphoid cells (CD69, forkhead box P3, CD223), B cells
(CD10, CD19, CD20, CD21, CD30, CD40, CD79, CD80,
CD81, IgM, IgD), or T cells (CD1a, CD3, CD4, CD5, CD7,
CD8, CD25, CD28, CD43, CD152, CD154). Similarly, there
was no change in the expression of cytokines preferentially
produced by Th1 cells, for example, Ifng and Tnf (interferon-g
and tumor necrosis factor-a), Th2 cells, for example, Il4, Il5,
and Il13 (IL-4, IL5, and IL-13), or in proinflammatory
cytokines Ccl5, Il1, Il6, Il10, Il12, and Tgfb1 (RANTES, IL-1,
IL-6, IL-10, IL-12, and transforming growth factor-b1). The
expression of genes encoding specific granulocyte markers was
not consistent: the expression of Fut9 that encodes fucosyl-
transferase 9, a critical enzyme for CD15 antigen synthesis,
was decreased by 1.8-fold, whereas Cd24a expression was
increased 1.4-fold in severely affected cpk kidneys.
C3 immunostaining pattern and content of activated C3 is
abnormal in the cpk kidneys
The complement system links the innate and adaptive
immune pathways.37 We found that the most consistently
overexpressed genes in severely affected cpk kidneys were
components of this system (Tables 2 and 5). One of the most
significantly overexpressed genes in severely affected cpk
kidneys was complement component 3 (C3; Table 3), a
central component of the complement system and major
activator of the innate immune response. To explore the
association of the C3 protein with PKD, we compared
the pattern of expression/deposition of antigenic C3 in
the kidneys of 10-day-old B6-cpk/cpk mice vs wild-type
littermates. Consistent with previous findings of C3 expres-
sion in all kidney segments,34 varying intensities of the C3
protein staining were detected in tubular epithelia of wild-
type kidneys (Figure 3a). In comparison, anti-C3 antibody
staining appeared to be more intense in tubular cells of cpk
kidneys (Figure 3b). In addition, the cpk kidneys contained a
larger number of peritubular cells that also stained strongly
with anti-C3 antibody and there was prominent C3 staining
of the cyst epithelial lining (Figure 3b, c and 4a–e). There was
no comparable tubular staining apparent in normal controls.
Table 3 | Most significantly overexpressed genes in severely affected cpk kidneys (by fold change)
Gene Change Function
Proposed PKD pathogenesis
component
Hp 4.7 Antioxidant; acute-phase reactant;
neovascularization mediator
Immune response, stress/ischemia/
trauma, vascular dysfunction
C3 3.9 Inflammatory mediator; regeneration mediator;
acute-phase reactant
Immune response, stress/ischemia/
trauma
Arg1 3.4 Arginine hydrolase; activated macrophage marker;
acute-phase reactant
Immune response
Actg2 3.3 Smooth muscle cells; neovascularization Vascular dysfunction
Lcn2 2.9 Iron transporter; acute renal failure marker; acute-
phase reactant
Stress/ischemia/trauma, immune
response
Saa3 2.9 Acute-phase reactant; secreted by macrophages Immune response
Ctss 2.8 Macrophage elastase Immune response
Sprr2f 2.8 Epithelial expression ?
Lrg1 2.7 Granulocytic differentiation marker Immune response
E430024C06Rik 2.7 ? ?
Ccl6 2.7 Monocyte chemotactic factor Immune response
Lzp-s 2.6 Antimicrobial agent; produced by macrophages;
acute-phase reactant
Immune response
Niban 2.6 ‘Protector against cell death under stress’ Stress/ischemia/trauma
Il18r1 2.6 Cytokine receptor; macrophage, NK and T-cell
marker
Immune response
1200016E24Rik 2.6 ? ?
Cd163 2.6 Macrophage Fe scavenger receptor; acute-phase
reactant
Immune response
Socs3 2.6 Blocks Jak/STAT pathway; predominantly
expressed in Th cells
Immune response
Serpine1 2.5 Complement inhibitor; acute-phase reactant Immune response
C1qb 2.5 Macrophage produced/macrophage activator Immune response
Timp1 2.5 Degradation of extracellular matrix; granulocyte
activator
Immune response
Cd14 2.5 Predominant expression: monocyte/macrophage;
acute-phase reactant
Immune response
F13a 2.5 Coagulation factor; predominant expression:
monocyte/macrophage
Immune response
Jak/STAT, Janus kinase/signal transducers and activators of transcription; PKD, polycystic kidney disease.
All listed genes had Po0.001.
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Table 4 | Macrophage-associated markers overexpressed in severely affected cpk kidneys
Cell type/process markers Gene Fold change Protein
Monocyte/leukocyte/lymphocyte Ccr2 2.1 monocyte chemoattractant protein (Mcp) 1 receptor
Ptprc 1.4 CD45 antigen
Monocyte/lymphocyte Ccr1 1.2 Mcp-3 and RANTES receptor
Monocyte/megakaryocyte Cxcl7 1.4 chemokine (C-X-C motif) ligand 7 (Pbp)
Monocyte and granulocyte Csf2rb1 1.8 colony stimul. factor 2 (GM-CSF) receptor, beta 1
Csf2rb2 1.8 colony stimul. factor 2 (GM-CSF) receptor, beta 2
Il3r 1.3 interleukin 3 receptor, alpha chain
Il6r 1.3 interleukin 6 receptor, alpha
Trem2 1.3 triggering receptor expressed on myeloid cells 2
Monocyte and macrophage CD14 2.5 CD14 antigen (LPS/apoptotic cell receptor)
CD68 1.6 CD68 antigen
CD163 2.6 CD163 antigen
Ifngr2 1.2 interferon gamma receptor 2
Csf1r 1.4 colony stimulating factor 1 (macrophage) receptor
Macrophage Mmd 1.3 monocyte to macrophage differentiation
Mpeg1 1.4 macrophage expressed gene 1
Msr2 1.5 macrophage scavenger receptor 2
Macrophage-alternatively activated Arg1 3.4 arginase 1
Ccl17 1.2 chemokine (C-C motif) ligand 17
Ccr5 2.1 Mcp-2 and Mip-1 alpha/beta receptor
F13a 2.5 coagulation factor XIII, alpha subunit
Fn1 1.3 fibronectin
Il1r1a 1.3 interleukin 1 receptor, type I (IL-1RA)
Il4ra 1.2 interleukin 4 receptor, alpha
Il10ra 1.2 interleukin 10 receptor, alpha
Il13ra 1.3 interleukin 13 receptor, alpha
Mrc1 1.7 mannose receptor 1
Saa3 2.9 serum amyloid A 3
Stab1 1.3 stabilin 1
Macrophage-resident Emr1 1.3 F4/80 homologue
Monocyte/leukocyte differentiation Cxcl4 1.4 chemokine (C-X-C motif) ligand 4 (Pf4)
Monocyte/leukocyte recruitment Ccl6 3.3 chemokine (C-C motif) ligand 6 (Mrp-1)
Ccl7 1.3 monocyte chemoattractant protein 3 (Mcp-3)
Ccl8 1.6 monocyte chemoattractant protein 2 (Mcp-2)
Ccl9 1.6 macrophage inflammatory protein-1 gamma
Ccl12 2.1 monocyte chemoattractant protein 5 (Mcp-5)
Cxcl16 1.3 chemokine (C-X-C motif) ligand 16
Thy1 1.8 thymus cell antigen 1, theta
Monocyte/leukocyte adhesion Itgb2 1.6 CD18 antigen (macrophage antigen 1, beta)
Itgam 1.6 CD11b antigen (macrophage antigen 1, alpha)
Selp 1.2 P selectin
Pathogen recognition Tlr4 1.5 Toll-like receptor 4 (CD14 receptor)
Macrophage activation Abca1 1.4 Abc1-ATP binding cassette transporter 1
Fcgr1 1.6 CD64 antigen (Fc receptor, IgG, high affinity I)
Fcgr2b 1.4 CD32 (Fc receptor, IgG, low affinity Iib)
Slpi 1.8 secretory leukocyte protease inhibitor
Phagocytosis Acta2 1.3 actin, alpha 2, smooth muscle, aorta
Actc1 1.5 actin, alpha, cardiac
Actg2 3.3 actin, gamma 2, smooth muscle, enteric
Coro1a 1.8 coronin 1a
Fcer1g 1.7 CD23 (Fc receptor, IgE, high affinity gamma)
Fcgr3 2.3 CD16 (Fc receptor, IgG, low affinity III)
Pxn 1.2 paxilin
Antigen presentation Cd86 1.3 CD86 antigen
(macrophage, dendritic, and B cell) Ii 2.2 ia-associated invariant chain (CD74)
H2-Aa 1.9 histocompatibility 2, class II antigen A, alpha
H2-Ab1 1.7 histocompatibility 2, class II antigen A, beta 1
H2-Eb1 1.7 histocompatibility 2, class II antigen E beta
Mr1 1.2 MHC, class I-related
Ctss 2.8 cathepsin S
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Further, we used immunoblotting to evaluate levels of
proteolytically activated C3 fragments in 10-day-old cpk and
wild-type kidneys. Consistent with the gene expression
profiling data, immunoblotting analyses showed that C3
protein levels were increased in the affected cpk kidneys, as
indicated by greater signal intensities of the 75 kDa C3
b-chains (bC3 in Figure 3e). The C3 b-chains are considered
the best quantitative marker of total C3 content because they
are not processed during the C3 activation. In contrast, the
C3 a-chains are sequentially degraded into smaller fragments
during complement activation (Figure 3d). We found
elevated levels of proteolytically activated C3 a-chain
fragments in the cpk vs wild-type kidneys (Figure 3e, iC3b
and asterisk). Altogether, these results are consistent with
increased C3 activity in the cpk kidneys.
Abnormal C3 activation as a general feature of RPKD
In addition, we have identified abnormalities in C3 proces-
sing in kidneys from other mouse PKD models: 6-, 14-, and
28-day-old BALB/c-bpk and 14-day-old FVB-orpk mice
(representative immunoblots are provided in Figure 3f and
g). These data suggest that abnormal C3 activation is a
general feature of RPKD. To further evaluate this hypothesis,
we tested kidneys from B21-week-old normal and RPKD
human fetuses. We observed that the specific C3 activation
fragment, C3d, was present in RPKD but not in normal
kidneys (Figure 3e). In addition, strong C3d staining was
observed in cystic RPKD epithelia (Figure 3i). The capacity of
cyst-forming RPKD epithelia to produce and activate C3 is
indicated by colocalization studies of C3 with collecting duct
cells identified by Dolichos biflorus agglutinin staining (Figure
4a–e), and further supported by the presence of both C3
mRNA (Figure 4f) and activated C3 protein fragments
(Figure 4g) in principal cells of a SV40-immortalized inner
medullary collecting duct (IMCD) cell line mIMCD-K2.
Abnormal C3 activation in RPKD kidneys may among other
effects activate macrophages that form CD68-positive inter-
stitial infiltrates in the vicinity of renal cyst as soon as at 21
weeks of gestation (Figure 4h). While the macrophages
themselves can produce complement, C3 staining of these
Table 5 | Expression of complement system genes in severely affected cpk kidneys
Gene Expression Change Protein
Adn Increased 1.7 adipsin (factor D)
BF — — factor B
C1qa Increased 2.4 complement component 1, q subcomponent, alpha polypeptide
C1qb Increased 2.2 complement component 1, q subcomponent, beta polypeptide
C1qg Increased 2.4 complement component 1, q subcomponent, gamma polypeptide
C1r — — complement component 1, r subcomponent
C1s — — complement component 1, s subcomponent
C2 — — complement component 2
C3 Increased 3.9 complement component 3
C3ar1 Increased 1.5 complement component 3a receptor 1
C4 — — complement component 4
C5r1 Increased 1.4 complement component 5 receptor 1
C5-C9 — — complement component 5-9 (common pathway)
Clu Increased 2.0 clusterin
Itgb2 Increased 1.6 complement component 3, receptor 3, beta polypeptide (CD18 antigen,
Mac-1 beta)
Itgam Increased 1.6 complement component 3, receptor 3, alpha polypeptide (CD11b
antigen, Mac-1 alpha)
Masp1 Increased 1.3 mannan-binding lectin serine protease 1
Mbl — — mannan-binding lectin
Pfc Increased 1.3 properdin
Serping1 Increased 1.5 serine (or cysteine) proteinase inhibitor, clade G, member 1
—, no change in gene expression between mildly and severely affected cpk kidneys.
Figure 3 | Antigenic C3 is present in increased amounts in cystic kidneys and is abnormally activated. (a) A representative micrograph
of an anti-C3-FITC conjugate-stained section of wild-type (þ /þ ) kidney showing little C3 protein. (b) Increased antigenic C3 in proximal
tubular cells in the cpk kidneys as well as linear staining of the collecting duct-derived cystic epithelia. (c) Higher magnification of dilated collecting
ducts with prominent anti-C3-FITC staining of cystic epithelia; nuclei were counterstained with the Hoechst 33528. (d) Schema demonstrating
generation of activated C3 fragments by sequential proteolytic cleavage at specific positions of C3 peptide. The individual proteolytic
fragments have specific biological effects (e.g., C3b is a major complement convertase, iC3b is a macrophage activator, C3d mediates antigen
presentation to B cells). Subsequent panels demonstrate abnormal C3 activation in cystic kidneys; immunoblotting with polyclonal anti-mouse
C3 antibody and kidney lysates from (e) 10-day-old cpk mice, (f) 14-day-old bpk mice, and (g) 14-day-old orpk mice. Kidneys from unaffected
littermates (þ /þ ) were used as controls. Each lane contains the same amount of protein; in addition, anti-b-actin antibody was used as a
loading control. The B40 kDa bands indicated by asterisk suggest abnormal content of iC3b and/or C3c and/or C3dg in the PKD kidneys.
(h) Immunoblotting using polyclonal anti-human C3d antibody demonstrated abnormal C3 activation in B21-week-old fetal RPKD vs control
kidneys. (i) Prominent C3d immunostaining of cystic epithelia that was observed in fetal RPKD kidney (B21 weeks of gestation), the control
staining with secondary antibody only was negative (j). Original magnification  100 (upper panels) and  400 (lower panels).
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infiltrates was weaker when compared to C3 staining of cystic
epithelia (Figure 4i). These results suggest that the comple-
ment is produced and activated in cystic RPKD epithelia,
providing a sensitive trigger for activation of macrophages
and the immune response in general.
DISCUSSION
To date, PKD research has largely focused on the exploration
of single genes, proteins, and pathways associated with
disease pathogenesis. However, recent advances in high-
throughput technology have led to the development of new
tools for more comprehensive whole-genome transcriptional
profiling and the application of these tools in PKD research.
We have identified four previous studies that used these high-
throughput tools to characterize PKD transcriptomes. While
there was no significant overlap among the specific genes
reported to be overexpressed in these studies, we found that a
substantial subset of these genes was overexpressed in severely
affected cpk kidneys in this study. For example, our study
identified 46% of genes overexpressed in ADPKD vs normal
epithelial cells and kidneys21 (Col1a1, Cspg2, Ctgf, Cxcl1, Fn1,
Fos, Krt1-19, Krt2-7, Lcn2, Myc, Pdlim1, and Tpm2), 13%
genes overexpressed in end-stage ADPKD kidneys vs chronic
allograft nephropathy vs normal kidneys kidneys22 (Fyb,
Fcgr1, Acta2, Cald1, Cnn1, Krt1-19, Lox, Ptprc, Ramp1,
Timp2, and Tagln), and 50% of reported overexpressed genes
in 3-week-old Cy vs wild-type rat kidney23 (Adamts1, Bgn,
Col12a1, Ctgf, Ctsd, Ctsk, Fn1, Lgals3, Ltbp2, Lyzs, Mgp,
Mmp14, Sdc1, Serpine1, Tgfb2, Timp2, and Vim). Moreover, a
closer examination of the previously identified PKD-
associated genes reveals that many of them are related to
immune response, consistent with data and the interpreta-
tions presented in this study. For example, at least 25% of the
reported overexpressed genes in the Cy rat kidney can be
associated with activated macrophages; for example, cathep-
sin D and K (Ctsd and Ctsk) are macrophage markers,
activated macrophages are the source of lysozyme (Lyzs),
fibronectin (Fn1), and vimentin (Vim), and they overexpress
Adamts1, Ctgf, Lgals3, Mmp14, and Serpine1. Taken together,
the parallels in gene expression profiles between the cpk
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Figure 4 | Antigenic C3 production by collecting duct cells. Representative micrographs of 10-day-old cpk kidneys show anti-C3d
staining (FITC; a), staining of collecting duct-derived cysts with Dolichos biflorus agglutinin (DBA-rhodamine; b), and their colocalization
on a merged image (c). Immunohistochemistry of sequential 3-mm thick sections shows similar colocalization pattern of (d) anti-C3d and
(e) DBA staining. The capacity of principal collecting duct cells to produce C3 is demonstrated on inner medullary collecting duct (IMCD)
cell line mIMCD-K2; reverse transcriptase-PCR with C3-derived primers produced cDNA-specific 200 bp product (asterisk, f), anti-C3d
immunoblotting of IMCD lysates showed activated C3 fragments (g). (h) The epithelial cell-derived complement may activate macrophages
that form CD68-positive interstitial infiltrates in RPKD kidneys as soon as at 21 weeks of gestation. (i) C3 staining of these infiltrates was
typically weaker when compared to cystic epithelial cells. Scale bar¼ 50mm.
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mouse model of RPKD, the Cy rat kidney model of
ADPKD,23 and ADPKD cystic epithelia21 suggest a common
role of the innate immune response in different forms of
PKD.
While the immune response association with PKD
pathogenesis was previously described in ADPKD, it was
primarily related to monocytic infiltrates and monocyte
chemoattractant protein 1.38 On the basis of the data
presented in this study, we propose that the number or
activity of monocyte/macrophage-like cells is also increased
in RPKD kidneys and that abnormal complement system
activation plays a central role in the activation of these cells.
Increased potential for abnormal complement system activity
is suggested by the overexpression of multiple genes encoding
components of all three (classical, alternative, and lectin)
complement activation pathways. Among them, the most
highly (3.9-fold) overexpressed complement component, C3,
plays key role because it is required in all three complement
activation pathways. We have shown that C3 is both
produced and activated at abnormally increased rates in
cpk, bpk, and human fetal RPKD kidney, and that it localizes
to cyst wall epithelia. While the abnormal C3 activation in
RPKD kidneys likely has numerous functional consequences,
the activation of complement receptor 3 (CR3; CD18/
CD11b) by the iC3b fragment of C3 may trigger the
profibrotic activity of alternatively activated macrophages.
We speculate that this profibrotic pathway represents one of
the C3-related biological processes that contribute to renal
disease progression in PKD.
We also suggest that some of the additional biological
effects or pathways triggered by the abnormal C3
activation can be deduced from gene expression profiles of
severely affected cpk kidneys. Specifically, we examined
the overexpression of multiple C3 receptors and their
signal-transduction pathways. These analyses revealed the
overexpression of C3a receptor and an iC3b receptor CR3
together with many proteins that are activated by these
receptors (Figure 5). Molecular pathways activated by these
two receptors involve the Rho-GTPase and src kinase families
that are essential components of cystogenic pathways in PKD
(reviewed in Torres and Harris39). Specifically, the C3a
receptor stimulates Rho-dependent transient formation of
actin stress fibers after coupling with overexpressed Ga13.
40
The Ga13 also stimulates Rho-dependent tyrosine phosphory-
lation of focal adhesion kinase and paxillin,41 other two
proteins involved in PKD pathogenesis (reviewed in Wil-
son42). In addition, CR3 leads to the activation of src kinase
family and this process is facilitated by CD87,43 which we
found to be overexpressed in severely affected cpk kidneys. In
addition, the activated C3 cleaves a complement component
5 (C5), and the resulting C5a fragment activates src kinase
family directly via the C5a receptor or by C5a receptor-
mediated cross-activation of the epidermal growth factor
(EGF) receptor.40 The src kinase family plays a central role in
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Figure 5 | Putative C3 signaling targets as indicated by overexpression in severely affected cpk kidneys and their relation to
cystogenesis. Both levels of C3 mRNA transcripts and C3 protein were increased in the cpk kidneys. Accelerated C3 processing in the
severely affected kidneys is suggested by overexpression of factor D and properdin and by increased iC3b levels in cpk kidneys. Only two
C3 receptors were overexpressed in severely affected kidneys: C3aR1 and CR3 (Mac-1; CD18/Cd11b; see Table 5). While C3aR1 couples with
specific G proteins involved in Rho activation, CR3 activates the src kinase family (and their targets) in the presence of LFA-1 and CD87. In
addition, src kinase family as well as EGF receptor (EGFR) may be activated by the C5a receptor (C5aR1) that was also overexpressed in
severely affected cpk kidneys. Since many of the downstream targets of the C3aR1, CR3, and C5Ra1 signaling that are overexpressed in
severely affected cpk kidneys (designated in red) are also involved in cystogenesis, these complement receptors may influence cystogenic
pathways related to the Rho, EGFR, or vasopressin receptor (Avpr2) signaling.
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the signaling of EGF and vasopressin receptors, and the
inhibition of either of these three proteins attenuates PKD
progression (reviewed in Torres and Harris39). Since renal
tubular cells express receptors for C3a and C5a,44,45 it is
conceivable that in addition to proinflammatory and
profibrotic effects, increased C3 activation in RPKD exacer-
bates cystogenesis by cross-activation of Rho-dependent and
src kinase family-associated pathways in renal tubular cells.
In summary, we have performed the first whole-genome
expression analysis and identified a subset of genes
specifically associated with disease progression in a subset
of phenotypically extreme RPKD kidneys. The PKD trans-
criptome of mildly affected kidneys resembled that of a
normal kidney. In contrast, genes encoding markers of the
innate immune response dominated the most highly over-
expressed genes in severely affected kidneys. Immunoblotting
and immunohistological analysis of other mouse PKD
models and human RPKD further demonstrate that increased
production and/or activation of C3 by cystic tubular cells
may play a critical role in PKD disease progression. Because
the innate immune response factors overexpressed in severely
affected kidneys included multiple markers associated with
alternatively activated macrophages (M2) that are critical
effectors of fibrosis, we speculate that increased M2-like
activity in PKD kidneys exacerbates development of PKD-
associated renal fibrosis, and this process further impairs
function of the residual renal parenchyma. In summary, our
whole genome-based observations suggest that the traditional
paradigm of PKD pathogenesis, in which an epithelial cell
defect leads to abnormal transport of numerous substrates,
abnormal proliferation and differentiation, and alteration of
extracellular matrix, does not fully explain transcriptional
changes associated with PKD progression identified by either
this study or other PKD transcriptional profiling studies.
Instead, renal disease progression in PKD appears to be
associated with several additional biological processes that
may have profound influence on the disease severity
(summarized in Figure 6). Among them, the most prominent
transcriptional abnormalities are related to innate immune
response. Therefore, we suggest that heightened activation of
innate immune system pathways plays a central role in PKD
progression, and that these pathways should be explored as
novel therapeutic targets that may slow the disease progression.
MATERIALS AND METHODS
Mice
Details describing the generation of the (B6-cpk/þ CAST)F1
intercross and subsequent identification of cpk mutants among the
F2 mice using Cys1cpk allele-specific assay were previously
described.13,31 All F2 mice were killed 10 days after birth, their
kidneys removed, and their length, weight, and volume recorded.
One of the kidneys from each animal was snap-frozen and stored in
liquid nitrogen, and the other was fixed in 10% buffered formalin
for histological evaluation. Additional B6 mice, either homozygous
for the cpk mutation or their wild-type (unaffected) littermates were
also killed at 10 days of age and their kidneys harvested. All
protocols were approved by the University of Alabama at
Birmingham Animal Care and Use Committee. The University of
Alabama at Birmingham is fully accredited by the American
Association of the Accreditation of Laboratory Animal Care.
Gene expression profiling
Phenotypic extremes among the cpk kidneys from the (B6-cpk/
þ CAST)F1 intercross were identified based on kidney length,
weight, and volume. The seven mildest and the seven most severely
affected kidneys representing phenotypic extremes (42 s.d.) were
used to prepare cRNA probes according to the GeneChip Expression
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Figure 6 | Proposed schema of PKD pathogenesis inferred from transcriptome profiling in 10-day-old cpk mice. In addition to the
traditional role of dysfunctional renal epithelia in PKD pathogenesis (shaded area), PKD progression was previously associated with several
other biological processes. Our data indicate that the innate immune response should be added as a contributant to this pathogenic schema.
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Analysis Manual (Affymetrix Inc., Santa Clara, CA, USA). In brief,
RNA was extracted with TRIzol Reagent (Invitrogen, Carlsbad, CA,
USA), and 20 mg of RNA was used for cDNA synthesis (Superscript
II Kit; Life Technologies, Rockville, MD, USA). Biotin-labeled cRNA
was generated from cDNA by in vitro transcription (ENZO BioArray
High Yield RNA Transcript Labeling Kit; Affymetrix). The integrity
of each of the 14 fragmented cRNA probes was tested by comparing
50 to 30 ratio of b-actin and GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) genes using the Affymetrix TestChip. Each cRNA
probe (15mg) was then hybridized to the low-density GeneChip;
Mouse U74Av2 Array (Affymetrix) that contains probes for
approximately 12 000 genes. The arrays were washed, stained, and
scanned according to the manufacturer’s instructions. Total kidney
RNAs were used for repeated gene expression profiling using whole-
genome high-density Affymetrix GeneChip Mouse Genome 430 2.0
Array (approximately 40 000 transcripts).
The summary signal intensity for each gene was computed using
the RMA default method46 that includes rma background correc-
tion, quantile normalization, and medium polish. The summary
signal intensities for individual genes were then used to assess
differential expression between the two groups of samples. Statistical
significance was assessed using permutation analysis,47 and the
resulting P-values were adjusted for multiple testing using the false
discovery rate as implemented in the R/qvalue software package.48,49
Validation of gene expression profiles
Large-scale validation of gene expression profiles was performed in
the R environment by correlating differentially expressed genes from
the Affymetrix U74Av2 and 430 2.0 arrays (Figure 1). Strong
correlations between the shared expression profiles across these two
array platforms (r¼ 0.72 for all genes, and r¼ 0.90 for differentially
expressed genes with false discovery rate adjusted Po0.05) provided
a formal large-scale validation of the expression data. In addition,
gene expressions of selected individual genes (for example, Kif12
and Ptprd) were tested by quantitative PCR and normalized using
the geometric mean of several housekeeping genes (Actb, Ubb,
and Ywhaz) by the GeNorm program50 (http://medgen.ugent.be/
~jvdesomp/genorm) as described previously.31
Functional annotation of the gene expression data sets
Biological interpretation of the identified differentially expressed
gene data sets was performed with a set of functional annotation
tools available from the Database for Annotation, Visualization and
Integrated Discovery version 2.1 (http://david.abcc.ncifcrf.gov).
These analyses included gene annotation enrichment analyses,
functional annotation clustering, BioCarta and KEGG pathway
mapping, ID translation, and homologue and literature match. A
subset of functional annotation analyses presented in Tables 2 and 3
was performed using the GO (http://ncbi.nlm.nih.gov) annotation
terms for biological process. Relationship of the identified individual
GO terms and their significance was visualized using the VisuaL
Annotation Display program (http://proto.informatics.jax.org/pro-
totypes/vlad-1.02/). In addition, a supervised approach based on an
extensive evaluation of published information available through the
PubMed and other NCBI databases (http://ncbi.nlm.nih.gov) was
applied to a subset of the most prominently expressed genes, and to
those genes that are known as markers of specific cell types (for
example, nephron segment-specific epithelial cells and inflammatory
cells), or genes that define critical components of specific molecular
pathways (for example, known PKD-associated pathways and
pathways related to inflammation).
Immunofluorescence and immunoblotting
Formalin-fixed kidneys from affected cpk homozygous and un-
affected wild-type B6 mice were paraffin embedded and cut into
sections (3 and 5 mm). These were xylen-deparafinized, rehydrated,
and stained using goat anti-mouse complement component 3 (C3)
polyclonal antibody conjugated with FITC (MP Biochemicals,
Sonlon, OH, USA) and Dolichos biflorus agglutinin–rhodamine or
horseradish peroxidase (Vector Laboratories, Burligame, CA, USA).
Immunostaining was performed after blocking tissue sections for
30 min with phosphate-buffered saline (PBS) containing 1% bovine
serum albumin (Sigma, St Louis, MO, USA). Primary antibody
diluted in blocking buffer was allowed to react with the tissues for
12 h at 4 1C followed by four rinses with PBS. Nuclei were stained
with Hoechst no. 33528 (Sigma) diluted 1:1000 in PBS, rinsed three
times in PBS, and then mounted in Prolong Gold antifade mounting
media (Molecular Probes, Eugene, OR, USA). Stained tissue sections
were analyzed using fluorescence or bright field microscopy using
the Leica HC microscope (Leica, Allendale, NJ, USA) and
MetaMorph software (Molecular Devices, Sunnyvale, CA, USA).
For immunoblotting, whole kidneys from three 10-day-old cpk
homozygotes with B6 genetic background, and kidneys from three
age-matched wild-type B6 mice were homogenized in lysis buffer
containing 150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 1% Nonidet P40,
0.5% sodium deoxycholate, 0.7% Pepstatin, and one tablet complete
protein inhibitor per 50 ml (Roche Diagnostics, Penzberg, Ger-
many). After 10 min centrifugation at 10 000 g, the supernatant
containing solubilized membranes as well as cytosolic material were
denatured for 5 min at 95 1C in  2 Laemmli reducing buffer, and
was separated by 4–12% gradient sodium dodecyl sulfate–polyacry-
lamide gel electrophoresis (Invitrogen). The gel was electrophor-
etically transferred onto a Hybond-ECL membrane (Amersham,
Piscataway, NJ, USA) using a wet blotter (Invitrogen). The
membrane was blocked with 5% non-fat milk in 1 PBS/0.05%
Tween 20 for 1 h at room temperature. Subsequent washing and
dilutions were done with 1 PBS/0.05% Tween 20 at room
temperature. The goat anti-C3 polyclonal antibody conjugated with
horseradish peroxidase (MP Biochemicals) was detected directly,
and anti-b-actin antibody (Sigma) was detected after incubation
with species-specific (mouse) secondary antibody conjugated with
horseradish peroxidase (Molecular Probes). Activated chemilumi-
nescence was captured on Hyperfilm-ECL (Amersham).
Tissues from bpk and orpk mice were collected and processed in
similar manner as described above for the cpk mice. Expression of
C3 protein in mIMCD-K2 cell line of SV40-transformed internal
medullary collecting duct cells (gift from Erik Schwiebert, University
of Alabama at Birmingham) was validated with reverse transcrip-
tase-PCR using intron-spanning primers that generate 200 and
376 bp products from cDNA and genomic DNA, respectively
(50-tgagtacaccatgaccatcca-30 and 50-tgtccttcccaatgatgtagc-30).
Remnant human fetal RPKD and non-PKD kidney were
collected after informed consent was obtained and according to
the protocol approved by the ethics committee of the University of
Alabama at Birmingham. The tissue processing, immunostaining,
and immunoblotting were performed as described above for mouse
tissues. However, we used a specific rabbit anti-human C3d
complement polyclonal antibody (Dako, Carpinteria, CA, USA) or
mouse anti-human CD68 antibody (Ventana Medical Systems,
Tucson, AZ, USA) and immunohistochemical detection with
preformed avidin: biotinylated enzyme complex (ABC) complex/
horseradish peroxidase and DAB chromogen (Dako) after blocking
with avidin/biotin blocking kit (Vector Laboratories).
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